On Feb. 20, we noted, “Keep an eye on Viking Therapeutics (VKTX). While the obesity drug stock has already exploded, it could see higher highs. At the moment, Viking Therapeutics and its potential obesity treatment – VK2735, has already shown a mean weight loss of up to 18 pounds from baseline.”
At the time, VKTX traded at around $35 a share. Today, it’s up to $85.05 and could see higher highs. All after its weight loss drug showed promising results in a mid-stage trial, as reported this week.
As reported by CNBC, “The trial followed more than 170 patients with obesity or who are overweight, some of whom received different dose sizes of the injectable drug or a placebo. Those who received weekly doses of the treatment lost up to 14.7% of their body weight from baseline, or 13.1% when adjusted for placebo, after 13 weeks.”
“Up to 88% of patients who received the drug, known as VK2735, achieved at least 10% weight loss, compared to just 4% of those who didn’t receive the treatment. Notably, there was no evidence of a plateau in weight reduction at week 13 for any dose of the drug, suggesting that ‘further weight loss might be achieved’ by keeping patients on the treatment longer, Viking CEO Brian Lian said during a call with investors.”
Plus, there are also rumors VKTX could potentially see interest from companies like Pfizer, as studies continue to show positive results.
Sincerely,
Ian Cooper
Recent Comments